Vogenx’s mizagliflozin is heading into Phase 2b testing for post-bariatric hypoglycemia (PBH). Amylyx Pharmaceuticals and Recordati are developing injectable peptide drugs for this metabolic disorder, but Vogenx aims to stand apart by offering patients a different mechanism of action and oral dosing.
The post Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs appeared first on MedCity News.
